WHO's in second?: A practical review of World Health Organization group 2 pulmonary hypertension
- PMID: 23918108
- PMCID: PMC3734892
- DOI: 10.1378/chest.12-2114
WHO's in second?: A practical review of World Health Organization group 2 pulmonary hypertension
Abstract
World Health Organization (WHO) group 2 pulmonary hypertension (PH) due to left-side heart disease (ie, heart failure or left-sided valvular heart disease) is the most common form of PH in western countries. Distinguishing patients with WHO group 2 PH, particularly the subset of patients with PH due to heart failure with preserved ejection fraction (HFpEF), from those with WHO group 1 pulmonary arterial hypertension (PAH) is challenging. Separating the two conditions is of vital importance because treatment strategies differ completely. Furthermore, therapies that are indicated for WHO group 1 PAH may be harmful in patients with WHO group 2 PH. We review the somewhat confusing PH nomenclature and the WHO classification system and rationale behind it. We then focus on left-side heart disorders that cause PH. An aging population and advances in the medical management of common cardiovascular disorders have caused the prevalence of heart failure to rise significantly, with more than one-half of patients having HFpEF. We review contemporary studies that focus on clinical and echocardiographic findings that help to distinguish HFpEF from PAH in the patient with PH. We discuss the typical, and sometimes atypical, hemodynamic profiles that characterize these two groups, review challenges in the interpretation of data obtained by right-sided heart catheterization, and highlight special maneuvers that may be required for accurate diagnosis. Finally, we review the largely disappointing studies on the use of PAH-specific therapies in patients with WHO group 2 PH, including the use of prostacyclins, endothelin receptor antagonists, and the more promising phosphodiesterase-5 inhibitors.
Figures
Comment in
-
Passive pulmonary hypertension: more than hydrostatics.Chest. 2014 Feb;145(2):413. doi: 10.1378/chest.13-1960. Chest. 2014. PMID: 24493517 No abstract available.
-
Response.Chest. 2014 Feb;145(2):413-4. doi: 10.1378/chest.13-2157. Chest. 2014. PMID: 24493518 No abstract available.
-
Pulmonary hypertension drugs were never properly tested in heart failure.Chest. 2014 Feb;145(2):420. doi: 10.1378/chest.13-2121. Chest. 2014. PMID: 24493528 No abstract available.
-
Response.Chest. 2014 Feb;145(2):420-1. doi: 10.1378/chest.13-2519. Chest. 2014. PMID: 24493529 Free PMC article. No abstract available.
-
Pulmonary hypertension.Chest. 2014 Feb;145(2):432-3. doi: 10.1378/chest.13-2359. Chest. 2014. PMID: 24493546 No abstract available.
-
Response.Chest. 2014 Feb;145(2):433. doi: 10.1378/chest.13-2694. Chest. 2014. PMID: 24493547 No abstract available.
References
-
- Oudiz RJ. Pulmonary hypertension associated with left-sided heart disease. Clin Chest Med. 2007;28(1):233-241 - PubMed
-
- Badesch DB, Champion HC, Sanchez MA, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;541):S55-S66 - PubMed
-
- Kovacs G, Berghold A, Scheidl S, Olschewski H. Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J. 2009;34(4):888-894 - PubMed
-
- Fang JC, DeMarco T, Givertz MM, et al. World Health Organization pulmonary hypertension group 2: pulmonary hypertension due to left heart disease in the adult—a summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2012;31(9):913-933 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
